Hemophilia Advisory Board
Steven Pipe, MD
PROFESSOR OF PEDIATRICS AND PATHOLOGY, MEDICAL DIRECTOR OF THE PEDIATRIC HEMOPHILIA AND COAGULATION DISORDERS PROGRAM AT THE UNIVERSITY OF MICHIGAN
Prof. Pipe completed his undergraduate medical training at the University of Toronto, Ontario, Canada, and his pediatric training at McMaster University in Hamilton, Ontario. His pediatric hematology and oncology training was completed at the University of Michigan.
*** PI in UniQure clinical trial, involved in BioMarin clinical trial
Annette Von Drygalski, MD, PharmD, RMSK
PROFESSOR OF CLINICAL MEDICINE, DIRECTOR OF THE HEMOPHILIA AND THROMBOSIS TREATMENT CENTER AT UCSD
Prof. von Drygalski completed fellowship training in hematology/oncology at UC San Diego School of Medicine. She earned her medical and pharmaceutical doctorates from the Ludwig Maximilian University in Munich, Germany.
*** involved in UniQure clinical trial
Glenn Pierce, MD, PhD
Board Director at the US National Hemophilia Foundation and World Federation of Hemophilia
Dr Pierce received both MD and PhD from Case Western Reserve University in Cleveland, Ohio and conducted postgraduate research in pathology and hematology research at Washington University in St. Louis, Missouri.
*** He has over 35 years’ successful biopharma R&D experience in protein and gene therapies, including executive positions at Biogen, Bayer and Amgen.
Steven Pipe, MD
PROFESSOR OF PEDIATRICS AND PATHOLOGY, MEDICAL DIRECTOR OF THE PEDIATRIC HEMOPHILIA AND COAGULATION DISORDERS PROGRAM AT THE UNIVERSITY OF MICHIGAN
Prof. Pipe completed his undergraduate medical training at the University of Toronto, Ontario, Canada, and his pediatric training at McMaster University in Hamilton, Ontario. His pediatric hematology and oncology training was completed at the University of Michigan.
*** PI in UniQure clinical trial, involved in BioMarin clinical trial
Annette Von Drygalski, MD, PharmD, RMSK
PROFESSOR OF CLINICAL MEDICINE, DIRECTOR OF THE HEMOPHILIA AND THROMBOSIS TREATMENT CENTER AT UCSD
Prof. von Drygalski completed fellowship training in hematology/oncology at UC San Diego School of Medicine. She earned her medical and pharmaceutical doctorates from the Ludwig Maximilian University in Munich, Germany.
*** involved in UniQure clinical trial
Glenn Pierce, MD, PhD
Board Director at the US National Hemophilia Foundation and World Federation of Hemophilia
Dr Pierce received both MD and PhD from Case Western Reserve University in Cleveland, Ohio and conducted postgraduate research in pathology and hematology research at Washington University in St. Louis, Missouri.
*** He has over 35 years’ successful biopharma R&D experience in protein and gene therapies, including executive positions at Biogen, Bayer and Amgen.
Gili Kenet, MD
PROFESSOR AND CHAIR OF THE HAEMATOLOGY DEPARTMENT AT THE SACKLER MEDICAL SCHOOL, TEL AVIV UNIVERSITY
Prof. Kenet received her Medical Degree from the Hebrew University in Jerusalem. She is Director of the Israel National Hemophilia Center in Tel Hashomer, Israel.
*** involved in BioMarin clinical trial
Mark A. Kay, MD, Ph.D
DENNIS FARREY FAMILY PROFESSOR IN DEPARTMENT OF PEDIATRICS, PROFESSOR OF GENETICS, STANFORD UNIVERSITY
Prof. Kay is the Dennis Farrey Family Professor and the Associate Chair for Basic Research in the Department of Pediatrics, Professor of Genetics and the Head of the Division of Human Gene Therapy at the Stanford University’s School of Medicine.
Gili Kenet, MD
PROFESSOR AND CHAIR OF THE HAEMATOLOGY DEPARTMENT AT THE SACKLER MEDICAL SCHOOL, TEL AVIV UNIVERSITY
Prof. Kenet received her Medical Degree from the Hebrew University in Jerusalem. She is Director of the Israel National Hemophilia Center in Tel Hashomer, Israel.
*** involved in BioMarin clinical trial
Mark A. Kay, MD, Ph.D
DENNIS FARREY FAMILY PROFESSOR IN DEPARTMENT OF PEDIATRICS, PROFESSOR OF GENETICS, STANFORD UNIVERSITY
Prof. Kay is the Dennis Farrey Family Professor and the Associate Chair for Basic Research in the Department of Pediatrics, Professor of Genetics and the Head of the Division of Human Gene Therapy at the Stanford University’s School of Medicine.